Last reviewed · How we verify
Placebo to match saxagliptin
This is an inert placebo formulation designed to match the appearance and administration of saxagliptin for blinded clinical trials.
This is an inert placebo formulation designed to match the appearance and administration of saxagliptin for blinded clinical trials. Used for Control arm in clinical trials of saxagliptin (DPP-4 inhibitor for type 2 diabetes).
At a glance
| Generic name | Placebo to match saxagliptin |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebos contain no active pharmaceutical ingredient and produce no pharmacological effect. They are used in randomized controlled trials to provide a control arm that is indistinguishable from the active drug in appearance, taste, and administration route, allowing for assessment of the true efficacy of the active comparator (saxagliptin) by controlling for placebo effect.
Approved indications
- Control arm in clinical trials of saxagliptin (DPP-4 inhibitor for type 2 diabetes)
Common side effects
Key clinical trials
- Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old (PHASE3)
- Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin (PHASE3)
- Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure (PHASE4)
- A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD (PHASE2, PHASE3)
- Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone (PHASE3)
- Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes (PHASE3)
- Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes (PHASE3)
- A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |